Clinical trials: Diabetic Macular Oedema
Diabetic Macular Edema
Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab
The aim of this study is to evaluate the one-year visual outcome and prognostic factors after intraocular injections of ranibizumab under pro re nata treatment regimen for the patients with diabetic macular edema (DME).
- Trial name
- IVRDME (NCT03973138)
- Testing
- Ranibizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular…
- Trial name
- ELARA (NCT06491914)
- Testing
- Aflibercept 8 mg
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 1,126 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Edema Due to Diabetes Mellitus
Home Monitoring of Diabetic Macular Edema
Diabetic macular edema (DME) is part of diabetic retinopathy (DR) and a leading cause of central visual loss in people with diabetes .
- Trial name
- NCT05223569
- Testing
- Home OCT monitoring model, Hospital-based monitoring with a staff-administrated OCT
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Age-related Macular Degeneration, Diabetic Macular Edema
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02118831
- Testing
- Blood Sample Collection, Aflibercept, Bevacizumab
- Volunteers
- 56 people
- Sponsor
- California Retina Consultants
Diabetic Retinopathy
Photobiomodulation for the Treatment of Diabetic Macular Edema
The current application proposes to conduct a prospective, clinical trial in diabetic subjects with diabetic macular edema (DME) to evaluate the therapeutic efficacy of 670 nm photobiomodulation on validated clinical outcome…
- Trial name
- PTDME (NCT02457975)
- Testing
- 670nm PBM, intravitreous VEGF-inhibitors
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Medical College of Wisconsin
Center-involved Diabetic Macular Edema
Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
Phase IIIb, multicenter, open-label, prospective, interventional study to assess the potential benefit of Aflibercept treatment administered IVT at a dosage of 2 mg with five monthly loading doses and then treat and extend over…
- Trial name
- NCT04288232
- Testing
- Aflibercept Injection [Eylea]
- Volunteers
- 45 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Diabetic Macular Edema (DME)
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
The purpose of this study is to evaluate the safety and efficacy of AKB-9778 administered as daily subcutaneous injections with and without monthly intravitreal injections of ranibizumab for 3 months in patients with diabetic…
- Trial name
- TIME-2 (NCT02050828)
- Testing
- AKB-9778, ranibizumab
- Where
- 39 sites in United States
- Volunteers
- 144 people
- Sponsor
- Aerpio Therapeutics
Macular Edema, Macular Degeneration
Implementation of the Intravitreal Injection Administered by Nurses
Introduction: Intravitreal injections involve medication administration into the eye to treat ocular diseases and protect vision.
- Conditions
- Macular Edema, Macular Degeneration, Diabetic Macular Edema
- Trial name
- NCT06511700
- Testing
- It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Corporacion Parc Tauli
Diabetic Macular Edema
Topical Nepafenac as Supplement for Diabetic Macular Edema
Diabetic macular edema (DME) is a major cause of visual loss in patients with diabetes mellitus. The standard treatment is with focal/grid laser therapy. Topical nepafenac was used as an adjunct therapy for treatment of DME.
- Trial name
- NCT02443012
- Testing
- Topical Gutt Nepafenac 0.1%, Laser
- Where
- 2 sites in Malaysia
- Volunteers
- 47 people
- Sponsor
- Universiti Sains Malaysia
Central Retinal Vein Occlusion With Macular Edema
Use of Ziv Aflibercept in Different Retinal Diseases
A prospective interventional case series study was conducted on 20 eyes of 20 patients with active myopic choroidal neovascularisation (CNV) ,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic central…
- Trial name
- NCT04290195
- Testing
- Ziv-Aflibercept 25 MG/ML [Zaltrap]
- Where
- Egypt
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Amin El Sayed Nawar
Diabetic Retinopathy
Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation
This exploratory study will compare the effects of ranibizumab treatment with conventional macular laser therapy for patients with diabetic macular oedema.
- Trial name
- LUCIDATE (NCT01223612)
- Testing
- Ranibizumab, Modified ETDRS laser
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Macular Edema
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.
- Trial name
- NCT02186119
- Testing
- abicipar pegol, ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 151 people
- Sponsor
- Allergan
Diabetic Macular Edema (DME)
Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and pilot efficacy of multiple ascending dose levels of AKB-9778 given as subcutaneous injections daily for 28 days in patients with…
- Trial name
- NCT01702441
- Testing
- Subcutaneous AKB-9778
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Aerpio Therapeutics
Diabetic Macular Edema
Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema
Anti-inflammatory or anti-angiogenic drugs play an ever- increasing role in the treatment of diabetic macular edema (DME). The drug delivery systems, such as injections of corticosteroid and or vascular endothelial growth factor…
- Trial name
- NCT05343156
- Testing
- Dexamethasone nanoparticles eye drops
- Where
- Denmark
- Volunteers
- 144 people
- Sponsor
- Oculis
Diabetic Macular Edema, Vogt Koyanagi Harada Disease
Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)
Suprachoroidal drug delivery is a recent route for managing various ocular conditions. Safety and long term results are still under investigations.
- Conditions
- Diabetic Macular Edema, Vogt Koyanagi Harada Disease, Retinal Vein Occlusion
- Trial name
- NCT05496530
- Testing
- Suprachoroidal triamcinolone acetonide injection
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Benha University
Macular Degeneration
Laser and Medical Treatment of Diabetic Macular Edema
This study will compare the side effects of two laser treatments for diabetic macular edema, a common condition in patients with diabetes.
- Trial name
- NCT00050479
- Testing
- Celecoxib (Celebrex)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Diabetic Macular Edema
Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema
The drug being tested in this study is low doses of Optina (formerly known as Danazol) (DMI-5207) that may be an effective treatment for diabetic retinopathy and diabetic macular edema (DME).
- Trial name
- NCT02002403
- Testing
- Danazol
- Volunteers
- 34 people
- Sponsor
- Unity Health Toronto
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Diabetic Macular Edema
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema
Diabetic macular edema refers to swelling (fluid accumulation) in the center of the retina. The retina is like the film of a camera and is located in the back of the eye.
- Trial name
- NCT02441907
- Testing
- aflibercept
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Unity Health Toronto